Clinical Research Fellow
Rob studied medicine at the University of Manchester and graduated in 2018, before moving to Oxford in 2020 to pursue specialty training in chemical pathology at the John Radcliffe hospital. Studying part-time, he completed an MSc in clinical biochemistry in 2022. His subspecialty interests include lipids and metabolic disorders.
Rob joined CTSU as a clinical research fellow in January 2024. He is working on both the ASCEND-PLUS trial, assessing oral semaglutide in people with diabetes, and the ORION-4 trial, evaluating the lipid-lowering drug inclisiran in people with pre-exisiting cardiovascular disease. He will also be working towards completion of a higher degree during his time at CTSU.